Literature DB >> 11861375

Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer.

Annegret Müller1, Tina Bocker Edmonston, Diana A Corao, Deborah G Rose, Juan P Palazzo, Heinz Becker, Robert D Fry, Josef Rueschoff, Richard Fishel.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant genetic predisposition syndrome that accounts for 2-7% of all colorectal cancers. Diagnosis of HNPCC is based on family history (defined by Amsterdam or Bethesda Criteria), which often includes a history of multiple synchronous or metachronous cancers. The majority of HNPCC results from germ-line mutations in the DNA mismatch repair (MMR) genes hMSH2 and hMLH1 with rare alterations in hMSH6 and hPMS2 in atypical families. Both HNPCC and sporadic MMR-deficient tumors invariably display high microsatellite instability (MSI-H). Two types of HNPCC families can be distinguished: type I (Lynch I) with tumors exclusively located in the colon; and type II (Lynch II) with tumors found in the endometrium, stomach, ovary, and upper urinary tract in addition to the colon. A proposed association of breast cancer with type II HNPCC is controversial. To address this important clinical question, we examined MSI in a series of 27 female patients who presented with synchronous or metachronous breast plus colorectal cancer. Although MSI-H was found in 5 of 27 (18.5%) of the colon cancers, in all cases the matched breast cancer was microsatellite stable. We also examined the breast tumors from three women who were carriers of MMR gene mutations from HNPCC families. None of these three breast tumors displayed MSI nor was the expression of MMR proteins altered in these tumors. We conclude that breast cancer largely arises sporadically in HNPCC patients and is rarely associated with the HNPCC syndrome.

Entities:  

Mesh:

Year:  2002        PMID: 11861375

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Axillary Metastasis as the First Manifestation of Occult Breast Cancer in a Male Patient.

Authors:  Guo-Li Gu; Shi-Lin Wang; Xue-Ming Wei; Li Ren; Fu-Xian Zou
Journal:  Breast Care (Basel)       Date:  2009-02-20       Impact factor: 2.860

Review 2.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

3.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.

Authors:  Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2010-05-21       Impact factor: 2.857

4.  Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry.

Authors:  Michael D Walsh; Daniel D Buchanan; Margaret C Cummings; Sally-Ann Pearson; Sven T Arnold; Mark Clendenning; Rhiannon Walters; Diane M McKeone; Amanda B Spurdle; John L Hopper; Mark A Jenkins; Kerry D Phillips; Graeme K Suthers; Jill George; Jack Goldblatt; Amanda Muir; Kathy Tucker; Elise Pelzer; Michael R Gattas; Sonja Woodall; Susan Parry; Finlay A Macrae; Robert W Haile; John A Baron; John D Potter; Loic Le Marchand; Bharati Bapat; Stephen N Thibodeau; Noralane M Lindor; Michael A McGuckin; Joanne P Young
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 5.  Surveillance in Lynch syndrome.

Authors:  Jukka-Pekka Mecklin; Heikki J Järvinen
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 6.  The tumor spectrum in the Lynch syndrome.

Authors:  Patrice Watson; Bronson Riley
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  Familial breast and bowel cancer: does it exist?

Authors:  Rodney J Scott; Katie A Ashton
Journal:  Hered Cancer Clin Pract       Date:  2004-02-15       Impact factor: 2.857

8.  Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins.

Authors:  Michael D Walsh; Margaret C Cummings; Sally-Ann Pearson; Mark Clendenning; Rhiannon J Walters; Belinda Nagler; John L Hopper; Mark A Jenkins; Graeme K Suthers; Jack Goldblatt; Kathy Tucker; Michael R Gattas; Julie L Arnold; Susan Parry; Finlay A Macrae; Michael A McGuckin; Joanne P Young; Daniel D Buchanan
Journal:  Mod Pathol       Date:  2013-02-01       Impact factor: 7.842

Review 9.  [Molecular pathology in hereditary colorectal cancer. Recommendations of the Collaborative German Study Group on hereditary colorectal cancer funded by the German Cancer Aid (Deutsche Krebshilfe)].

Authors:  J Rüschoff; B Roggendorf; F Brasch; M Mathiak; D E Aust; J Plaschke; W Mueller; C Poremba; M Kloor; G Keller; M Muders; S Blasenbreu-Vogt; P Rümmele; A Müller; R Büttner
Journal:  Pathologe       Date:  2004-05       Impact factor: 1.011

Review 10.  Cancer risk in Lynch Syndrome.

Authors:  Emma Barrow; James Hill; D Gareth Evans
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.